Posters & Publications

Posters & Publications

2019

Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy. Latil et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

 

In vivo effects of Sarconeos (API BIO101) on mouse model of severe spinal muscular atrophy. Belzier et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

In MYODA clinical program: A new approach unraveling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages. Chabane et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD. Chabane et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

SARCONEOS (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting. Dilda et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging.

Evaluation of safety and efficacy of BIO101, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging.

Designing a clinical program for BIO101, a Mas receptor activator to target Age-related sarcopenia. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

2018

BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells. Serova et al. Oral presentation at the 11th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018; 9; 1170. Abstract 4-11.

Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101). Dioh et al. Oral presentation at the 11th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018 Dec; 9(6); 1172. Abstract 5-01.

Effects of Sarconeos (API BIO101) on in vivo and in vitro models of Duchenne muscular dystrophy. Dilda et al. Poster presentation at the 23rd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2018, Mendoza, Argentina.

Abstract published in Neuromuscular Disorders, 28 (Suppl.2) S143, P206.

Combined effects of BIO101 on anabolism and mitochondrial function in skeletal muscle cells. Serova et al. Oral and poster presentations at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 72. Abstract OC12.

SARA-INT, A double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of Sarconeos (BIO101). Dioh et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA

SARA-OBS, an observational study dedicated to characterize Age-related Sarcopenia population suitable for interventional studies. Dioh et al. Oral presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 72. Abstract OC44.

Daily Mobility profile in Age-Related Sarcopenia: Actimetry baseline data from SARA-OBS, a six-month observational multicentre clinical study in EU and US. Zia et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 128. Abstract P110.

BIO103 demonstrates sharp improvement of skeletal muscle function in an animal model of hindlimb immobilization. Latil et al. Poster presentation at the 9th International Conference on Frailty & Sarcopenia Research (ICFSR), March 1-3, 2018, Miami, USA.

Abstract published in The Journal of Frailty & Aging, 7(1), 128-129. Abstract P113.

 

2017

BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09.

SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial. Dioh et al. Poster presentation at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle8, 1073-1074. Abstract 9-02

Sarconeos, a drug candidate in clinical development for Sarcopenia, demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy. Dilda et al. Poster presentation at the 22nd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2017, Saint Malo, France.

 

BIO103, a second-generation compound for the treatment of sarcopenia. From anabolic properties to the reversion of aging-related functional loss. Dilda et al. Poster presentation at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging. 6(S1), 146, Abstract 217.

SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers. Dioh et al. Oral and poster presentations at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging. 6(S1), 28, Abstract OC38.

 

2016

BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. Dilda et al. Poster presentation at the 9th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle7(5), 655. Abstract 4-01.

A randomized, placebo-controlled trial to evaluate the efficacy and safety of BIO101 on Sarcopenic Obesity. Dioh et al. Poster presentation at the 7th International Conference on Frailty & Sarcopenia Research (ICFSR), April 28-29, 2016, Philadelphia, USA.

Abstract published in The Journal of Frailty & Aging, 5, S1, 75, Abstract P53.

 

2015

BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France.

Abstract published in Journal of Cachexia, Sarcopenia and Muscle6(4), 429. Abstract 1-76.

 

2014

The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain.

Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.